CC
FULC icon

Casdin Capital’s Fulcrum Therapeutics FULC Stock Holding History

Casdin Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,154,476
Closed -$12.1M – 56
2021
Q2 		$12.1M Sell
1,154,476
-86,700
-7% -$877K 0.31% 41
2021
Q1 		$14.6M Hold
1,241,176
– – 0.44% 37
2020
Q4 		$14.5M Sell
1,241,176
-200,000
-14% -$2.26M 0.43% 39
2020
Q3 		$11.4M Hold
1,441,176
– – 0.51% 34
2020
Q2 		$26.4M Buy
1,441,176
+231,891
+19% +$3.65M 1.56% 22
2020
Q1 		$14.4M Sell
1,209,285
-30,000
-2% -$480K 1.53% 20
2019
Q4 		$20.6M Buy
1,239,285
+395,000
+47% +$3.78M 1.9% 17
2019
Q3 		$5.61M Buy
+844,285
New +$9.34M 0.58% 29

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Casdin Capital's FULC Position: Q3 2021 in Review

Casdin Capital sold out of Fulcrum Therapeutics (FULC) in Q3 2021, closing a stake of 1,154,476 shares — an estimated $12.1M sold.

Casdin Capital first reported a position in FULC in Q3 2019 and held it in 8 quarters. The position peaked at $26.4M in Q2 2020. 101 funds tracked by Wall St. Rank hold FULC as of Q3 2021.

  • Casdin Capital reported no remaining Fulcrum Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Casdin Capital sold 1,154,476 Fulcrum Therapeutics shares in Q3 2021, an estimated $12.1M.
  • Casdin Capital first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 8 quarters.
  • Casdin Capital's Fulcrum Therapeutics position peaked at $26.4M in Q2 2020.
  • 101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2021.

Based on Casdin Capital's 13F filing for Q3 2021, filed 15 Nov 2021.